COVID-19: media coverage of YUMAB’s activities – ARCHIVE

ARCHIVE

Media coverage of YUMAB’s activities in COVID-19 R&D
(mainly German)

June 06, 2020

“Gemeinsam gegen Covid-19”
transkript.de
Special status report on YUMAB’s development of a therapeutic coronavirus antibody.

May 25, 2020

“Schnelle, sichere und zuverlässige Entwicklung passender Antikörper”
Bionity.com
Interview with YUMAB founders about positioning as a start-up in a competitive market.

May 17, 2020

“Corona-Impfstoff: Wo Forscher ansetzen”
ZDF
Summary of current activities in Germany to find vaccines and therapies against SARS-CoV-2.

May 17, 2020

“德國新冠合成抗體研發取得突破”
(Deutschland’s neuer Durchbruch in der Forschung und Entwicklung von synthetischen Antikörpern)
Phoenix Television Info News Kanal (Chinesisch)
TV-report about Germany’s activities in coronavirus research and therapy, including a statement of Prof. Stefan Dübel.

May 14, 2020

“Braunschweiger Biotech-Pionier entwickelt therapeutischen SARS-CoV-2 Antikörper”
Bionity.com
Coverage of YUMAB’s press release regarding the cooperation with the CORAT consortium in R&D of a coronavirus antibody therapy.

May 14, 2020

“Antikörper sollen SARS-CoV-2 neutralisieren”
Deutsche Apothekerzeitung Online
Report of YUMAB’s coronavirus antibody discovery efforts.

May 14, 2020

“Other news to note for May 14”
BioWorld
Note about YUMAB’s coronavirus antibody discovery efforts.

May 14, 2020

“First COVID-19 neutralizing antibody detected”
NLC
Coverage of YUMAB’s press release regarding the successful testing of neutralizing coronavirus antibodies by the HZI.

May 13, 2020

“Yumab identifies COVID-19 antibody therapy”
The Science Advisory Board
Report about YUMAB’s cooperation with the CORAT consortium in the development of a coronavirus antibody therapy.

May 13, 2020

“Gute Nachrichten aus Niedersachsen: Wichtiger Erfolg der Infektionsforschung zur Bekämpfung der Corona-Pandemie”
Speech of the Minister for Science and Culture of Lower Saxony, Björn Thümler before the State Parliament
Briefing about the coronavirus R&D activities in Lower Saxony, YUMAB’s contribution and the funding situation in the state.

May 13, 2020

“Landtag würdigt Braunschweiger Corona-Forschung”
Braunschweiger Zeitung
Coverage of Minister Thümler’s speech.

May 12, 2020

“YUMAB Identifes Promising Candidate for COVID-19 Antibody Therapy”
PRNewswire
YUMAB statement on the successful testing of new SARS-CoV-2 antibody candidates for COVID-19 by the HZI.

May 12, 2020

“YUMAB Identifes Promising Candidate for COVID-19 Antibody Therapy”
German Biotech Database
Coverage of YUMAB’s statement on the successful testing of new SARS-CoV-2 antibody candidates for COVID-19 by the HZI.

May 12, 2020

“YUMAB Identifes Promising Candidate for COVID-19 Antibody Therapy”
finanzen.net
Coverage of YUMAB’s press release regarding the SARS-CoV-2 antibody discovery.

May 12, 2020

Antikörpertherapie gegen Covid-19
GIT Laborportal
Report about HZI and CORAT consortium testing of YUMAB’s coronavirus antibody candidates.

May 11, 2020

Corona Heilmittel: Interview mit Dr. André Frenzel, YUMAB, Braunschweig
Radio SAW
Podcast interview (German) with YUMAB’s CSO André Frenzel who explains the technology behind the discovery of new therapeutic SARS-CoV-2 antibody candidates.

May 11, 2020

“Corona-Antikörper gefunden: Forscher aus Braunschweig melden Durchbruch”
MK kreiszeitung.de
Short report about YUMAB’s latest breakthrough in SARS-CoV-2 antibody discovery.

May 11, 2020

YUMAB identifies promising candidate for Covid-19 antibody therapy
BioRN
Coverage of YUMAB’s press release regarding the SARS-CoV-2 antibody discovery.

May 11, 2020

Das Virus ausschalten
Tagesspiegel.de
Report about the coronavirus antibody discovery activities at the HZI and YUMAB.

May 08, 2020

Weil und Thümler informieren sich über Coronaforschung am HZI
Braunschweiger Zeitung
News about Lower Saxony’s state premier Stephan Weil (SPD) and science minister Björn Thümler (CDU) visiting the Helmholtz-Center for Infection Research in Braunschweig to obtain first-hand information on the progress in coronavirus antibody development.

May 07, 2020

“Braunschweiger Forscher melden wichtigen Schritt im Kampf gegen Coronavirus”
SAT.1
News about testing of YUMAB’s SARS-CoV-2 antibody candidates by virologist Luka Cicin-Sain at the Helmholtz-Center for Infection Research.

May 07, 2020

Hope for antibody therapy against Covid-19
HZI
Documentation of preclinical tests on YUMAB’s SARS-CoV-2 antibody candidates conducted by virologist Luka Cicin-Sain at the Helmholtz-Center for Infection Research.

May 06, 2020

Corona-Medikament rückt näher
NDR
Report about the cooperation of YUMAB with the Helmholtz Center for Infection Research in the development of a therapeutic antibody against SARS-CoV-2.

May 06, 2020

Kampf gegen Corona: Braunschweiger Forscher melden Durchbruch
Braunschweiger Zeitung
Interview with virologist Luka Cicin-Sain whose team at the Helmholtz Center for Infection Research has confirmed the ability of YUMAB antibodies to prevent coronavirus from entering the host cell.

May 06, 2020

“Durchbruch in Braunschweiger Corona-Forschungprojekt um HZI, TU Braunschweig und Yumab – Dr. Christos Pantazis und Annette Schütze fordern Unterstützung des Landes”
SPD
Statement of the SPD party regarding state funding for coronavirus R&D in Lower Saxony.

May 06, 2020

Hochleistung unter erschwerten Bedingungen
Besser smart – Das Innovationsportal
Interview with CEO Thomas Schirrmann on YUMAB’s development of SARS-CoV-2 blocking antibodies.

May 06, 2020

“Eindeutig ein Durchbruch” – Forscher kommen offenbar Covid-19-Medikament näher
Stern.de
Report about virologist Luka Cicin-Sain whose team at the Helmholtz Center for Infection Research has confirmed the ability of YUMAB antibodies to prevent coronavirus from entering the host cell.

May 06, 2020

Die Jagd nach dem Corona-Medikament: Deutsche Forscher sprechen von “Durchbruch”
Focus online
Report about virologist Luka Cicin-Sain whose team at the Helmholtz Center for Infection Research has confirmed the ability of YUMAB antibodies to prevent coronavirus from entering the host cell.

May 06, 2020

“Braunschweiger Forscher entdecken Corona-Blocker”
web.de
Report about virologist Luka Cicin-Sain whose team at the Helmholtz Center for Infection Research has confirmed the ability of YUMAB antibodies to prevent coronavirus from entering the host cell.

May 06, 2020

Antikörper gesucht: YUMAB aus Braunschweig will Corona bekämpfen
Startup Niedersachsen / BioRegioN
Interview with CEO Thomas Schirrmann on YUMAB’s development of SARS-CoV-2 blocking antibodies.

May 05, 2020

“Deutsche Forscher finden Corona-Blocker”
n-tv.de
Report about virologist Luka Cicin-Sain whose team at the Helmholtz Center for Infection Research has confirmed the ability of YUMAB antibodies to prevent coronavirus from entering the host cell.

May 05, 2020

“Braunschweiger Forscher melden Erfolg im Kampf gegen Corona”
Berliner Morgenpost
Report about virologist Luka Cicin-Sain whose team at the Helmholtz Center for Infection Research has confirmed the ability of YUMAB antibodies to prevent coronavirus from entering the host cell.

May 05, 2020

Braunschweiger Antikörper-Spezialist im Gespräch: „Yumab“-Mitbegründer Dr. André Frenzel rechnet mit zweiter Welle
Radio Okerwelle
Interview with YUMAB founder André Frenzel about the science and technology behind the generation of a novel coronavirus antibody.

May 05, 2020

“Braunschweiger Forscher weisen Antikörper gegen Sars-CoV-2 nach”
Epoch Times
Report about virologist Luka Cicin-Sain whose team at the Helmholtz Center for Infection Research has confirmed the ability of YUMAB antibodies to prevent coronavirus from entering the host cell.

April 22, 2020

“Auf der Suche nach dem optimalen Antikörper – So will YUMAB Corona bekämpfen”
regionalHeute.de
Coverage of the visit of Lower Saxony’s health minister Dr. Carola Reimann’s to YUMAB.

April 20, 2020

“DACH-Unternehmen im Kampf gegen COVID-19”
transkript
Overview of COVID-19 R&D activities and companies in the DACH-region.

April 15, 2020

“Systemrelevante Pharmaforschung”
Blog der Republik
Short report about the status of pharmaceutical R&D in times of coronavirus.

April 08, 2020

“Boehringer Ingelheim bleibt trotz Corona auf stabilem Kurs”
Handelsblatt
More than 100 scientists at Boehringer Ingelheim push the company’s new coronavirus R&D efforts in cooperation with partners – one of them is YUMAB.

April 07, 2020

“Therapeutic medicines against the coronavirus infection Covid-19”
VfA
Overview of ongoing projects for repurposing of therapeutic medicines against coronavirus and new developments.

April 02, 2020

“Im Kampf gegen Corona – Braunschweiger Firma forscht mit Antikörpern”
BILD
YUMAB’s research sets important impulse in the development of a SARS-CoV-2 antibody-therapy.Minister for Economy, Bernd Althusmann discusses the strategy with CEO Thomas Schirrmann and CSO André Frenzel.

April 01, 2020

“Biotech-Firma forscht an Antikörpern gegen Sars-CoV-2”
Süddeutsche Zeitung
Coverage of Bernd Althusmann’s visit.

April 01, 2020

“Braunschweiger Start-up gelingt wichtiger Schritt im Kampf gegen das Coronavirus”
SAT.1-Video
Coverage of Bernd Althusmann’s visit.

April 01, 2020

“Corona-Antikörper: “Frage ist nicht ob, sondern wann es klappt”
Braunschweiger Zeitung
Coverage of Bernd Althusmann’s visit.

March 30, 2020

“In Vitro Technology Developers Step Up To Help With Coronavirus Research and Testing”
Good Science Digest
Overview of current in vitro techniques in coronavirus R&D and companies that apply them.

March 29, 2020

Coronavirus in the crosshairs, Part 4: Antibody therapeutics
Antibody Society
Overview of ongoing efforts towards the discovery and development of coronavirus therapeutics.

March 26, 2020

“Braunschweiger Firma forscht an einer Coronavirus-Antikörper-Therapie”
Braunschweiger Zeitung
Interview with YUMAB founders Stefan Dübel and Thomas Schirrmann in which they explain YUMAB’s approach for an antibody-based COVID-19 therapy.

March 25, 2020

“COVID-19: First step towards antibody therapy by YUMAB”
BioRN
Partnership of Boehringer Ingelheim and YUMAB yields in receptor blocking antibodies against SARS-CoV-2.